2024-2025 RSV PREVENTION CLINIC REFERRAL



In order to process this referral, we must have:

- Hospital Discharge Summary (from Infant's Birth) & Recent Outpatient Notes
 AND
- 2. This referral form completed entirely (may include patient's face sheet)

Child's name			DOB	Today's Date	
Address			Telephone Number		
Father's Name			Alternative number		
Mother's N	Nother's Name			Mother's work number	
Primary Care Provider/phone number			Referral Source/phone # (if different that PCP)		
Primary In	surance Company	Insurance Co Phone #	IPA or Medical C	Group (if HMO insurance)	
Policy #		Group #	Insured Name	Insured Name	
No	nagis or Beyfortus Dose given: Date te: All Children < 8 months of	sk children and those seen	tus but RSV p	revention clinic can only	
	Preterm: Infants bom ≤ 28 weeks 6 days ges 2024	station and less than 8 months of age (Bo	eyfortus) or less than 1	2 months of age (Synagis) as of 1 Oct	
	□ Chronic Lung Disease: Preterm infants with CLD of prematurity born at less than 32 weeks gestation and less than 8 months of age (Beyfortus less than 12 months of age (Synagis) as of 1 Oct 2024.				
	Infants with CLD of prematurity and continue to require medical support (e.g., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) during the past 6 months and less than 19 months of age (Beyfortus) or less than 24 months of age (Synagis) as of 1 Oc 2024				
	Congenital Heart Disease: Infants less than 8 months of age (Beyfortus) or less than 12 months of age (Synagis) as of 1 Oct 2024 with hemodynamically significant CHD (includes those infants with acyanotic heart disease who are receiving medication to control congestive heart failure and will require cardiac surgical procedures and infants with moderate to severe pulmonary hypertension).				
	Cardiac Transplantation: Children less than 8 months of age (Beyfortus) and less than 24 months of age as of 1 Oct 2024 who undergo cardiac transplantation during the RSV season.				
	Pulmonary Abnormality or Neuromuscular Disorder: Infants, less than 8 months of age (Beyfortus) and less than 12 months of age (Synagis) as of 1 Oct 2024 with neuromuscular disease or congenital anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough.				
	□ Severe Immunocompromise: Children less than 19 months of age (Beyfortus) or less than 24 months of age (Synagis) as of 1 Oct 2024 who are profoundly immunocompromised during the RSV season.				
	☐ American Indian and Alaska Native Childre: children less than 19 months of age (Beyfortus) as of 1 Oct 2024				
	□ Cystic Fibrosis: Infants less than 19 months of age who have manifestation of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persistent when stable) or weight-for length <10 percentile (Beyfort				
	Print Referring Provider's Name	Provider's Signature indic	ating authorization	for referral	

Fax Referral to CHOC in Orange at 1-855-CHOCFAX (1-855-246-2329)
For scheduling call (714) 509-7983. For authorizations call (714)930-1711.

To reach the clinical team call (714) 509-4107

99178 (Rev.09/2024)